Physician profile
Jeny Varghese
NPI 1831487974
$4,843.12
in general payments reported to CMS, 2019-2025
22 companies · $952 in 2025
The $952 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $165 · 2021: $418 · 2022: $419 · 2023: $715 · 2024: $1,235 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880 · Education: $22.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.63 |
| Education | $22.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $917.48 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $876.64 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $560.92 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $437.02 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $235.53 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $203.92 | 2021-2024 | Lupkynis |
| Akebia Therapeutics INC | $201.09 | 2019-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $189.59 | 2024-2025 | |
| Travere Therapeutics, INC. | $189.34 | 2022-2025 | |
| Ardelyx, INC. | $187.69 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $166.55 | 2024-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $161.04 | 2023-2024 | Benlysta, Jesduvroq |
| Takeda Pharmaceuticals U.S.A., INC. | $90.61 | 2021-2023 | Gattex |
| Mallinckrodt Enterprises LLC | $90.56 | 2019 | |
| Fresenius USA Manufacturing, INC. | $67.14 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $66.54 | 2019 | |
| Calliditas Therapeutics US INC. | $60.64 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $46.12 | 2024 | |
| Lilly USA, LLC | $30.61 | 2024 | Jardiance |
| Renalytix Ai, INC. | $23.71 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Hospital Products INC. | $23.14 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeny Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.